"Dyslipidemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Descriptor ID |
D050171
|
| MeSH Number(s) |
C18.452.584.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dyslipidemias".
Below are MeSH descriptors whose meaning is more specific than "Dyslipidemias".
This graph shows the total number of publications written about "Dyslipidemias" by people in this website by year, and whether "Dyslipidemias" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 5 | 0 | 5 |
| 2006 | 7 | 2 | 9 |
| 2007 | 3 | 3 | 6 |
| 2008 | 9 | 4 | 13 |
| 2009 | 2 | 3 | 5 |
| 2010 | 4 | 1 | 5 |
| 2011 | 4 | 2 | 6 |
| 2012 | 5 | 2 | 7 |
| 2013 | 3 | 0 | 3 |
| 2014 | 4 | 1 | 5 |
| 2015 | 5 | 1 | 6 |
| 2016 | 0 | 1 | 1 |
| 2017 | 6 | 2 | 8 |
| 2018 | 6 | 3 | 9 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 2 | 0 | 2 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dyslipidemias" by people in Profiles.
-
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026 Apr 28; 153(17):e1154-e1276.
-
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 May 19; 87(19):2624-2757.
-
Long-term impact of dyslipidemia on sac dynamics after endovascular aortic repair for abdominal aortic aneurysms in the GREAT registry: An insight in dyslipidemia using propensity matched controls. Vascular. 2026 Jun; 34(3):525-537.
-
Lower Serum Triiodothyronine Levels Constitute an Independent Risk Factor for Dyslipidemia in Levothyroxin-Treated Patients. Endocr Pract. 2026 Feb; 32(2):135-141.
-
Small dense low-density lipoprotein cholesterol and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis. Eur J Prev Cardiol. 2024 Jun 03; 31(8):1048-1054.
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 09; 64(9):1150-1164.
-
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):148-155.
-
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022 08; 28(8):1672-1678.
-
Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc Res. 2022 01 29; 118(2):413-423.
-
Chrysanthemum morifolium Flower Extract Ameliorates Obesity-Induced Inflammation and Increases the Muscle Mitochondria Content and AMPK/SIRT1 Activities in Obese Rats. Nutrients. 2021 Oct 19; 13(10).